Highlights Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2024-12-05 EST			5-day change	1st Jan Change
4,138.00 ^JPY	+0.07%		+0.85%	+2.07%

12-03	Keros Therapeutics, Takeda in Elritercept Licensing Pact	DJ
12-03	Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keros Therapeutics, Takeda in Elritercept Licensing Pact	12-03	DJ
Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept	12-03	MT
Hutchmed Announces Launch by Takeda of Fruzaqla (Fruquintinib) in Japan	11-22	CI
Hutchmed to get payment from Takeda as Fruzaqla launched in Japan	11-22	AN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda Pharmaceutical Company Limited to Develop Cell Therapy Platform	11-20	CI
Hutchmed China receives first milestone payment for Takeda drug sales	10-31	AN
Takeda Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended September 30, 2024	10-31	CI
Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2025, Payable on December 2, 2024	10-31	CI
Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised	10-31	MT
Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update	10-31	DJ
Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance	10-31	DJ
Japan's Takeda raises full-year profit forecast amid restructuring	10-31	RE
Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024	10-31	CI
Takeda Pharmaceutical, Boston Medical Center Team Up for Decarbonization Project	10-24	MT
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem	10-24	CI
Takeda Forms Joint Venture With Astellas, Sumitomo Mitsui to Develop Early-Drug Discovery Programs in Japan	10-09	MT
Galecto to Focus on Cancer, Liver Disease After Strategic Review; Shares Fall	10-07	MT
Ex-dividend day for interim dividend	09-26	FA
Tempus AI Expands Takeda Partnership to Support Cancer Drug Research	09-26	MT
Alvotech Starts Confirmatory Study for Biosimilar Candidate to Entyvio	09-25	MT
Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing	09-24	AN
Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer	09-24	CI
Lupin Limited Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company Limited to Commercialize Vonoprazan	09-18	CI
Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder	08-07	MT
Takeda Receives European Commission Approval for ADZYNMA®	08-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Highlights

Filters